CoSara Receives CDSCO’s Approval for its Saragene COVID-19 2-Gene Multiplex Test

 CoSara Receives CDSCO’s Approval for its Saragene COVID-19 2-Gene Multiplex Test

CoSara Receives CDSCO’s Approval for its Saragene COVID-19 2-Gene Multiplex Test

Shots:

  • Co-Diagnostics’ JV CoSara has received CDSCO’s clearance to manufacture and sell its Saragene COVID-19 2-gene multiplex RT-PCR test as an IVD, intended for the qualitative detection of the SARS-CoV-2 virus
  • The kit leverages CoPrimer technology & is based on a test originally designed by Co-Diagnostics, who secured CE marking for its Logix Smart SARS-CoV-2 multiplex test in Feb’2020
  • To identify the virus presence, both the tests target two gene markers of the SARS-CoV-2 genome i.e. RdRp and E-gene. Additionally, CoSara prior received CDSCO’s approval for RT-PCR tests for mycobacterium tuberculosis, malaria, hepatitis B & C and HPV to be manufactured & sold as IVDs in India

Click here ­to­ read full press release/ article | Ref: Co-Diagnostics | Image: Co-Diagnostics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post